Examples of 'regorafenib' in a sentence
Meaning of "regorafenib"
regorafenib (adjective) - a pharmaceutical term used to describe a specific type of drug or medication
Show more definitions
- A particular oral multi-kinase inhibitor
How to use "regorafenib" in a sentence
Basic
Advanced
regorafenib
The pharmacokinetics of regorafenib is not influenced by gender.
Stivarga contains the active substance regorafenib.
Regorafenib is eliminated mainly via the hepatic route.
There are no data on the use of regorafenib in pregnant women.
Stivarga is an anticancer medicine that contains the active substance regorafenib.
There is limited data on regorafenib in the black patient population.
Preference is given to the monohydrate of regorafenib.
It is unknown whether regorafenib or its metabolites are excreted in human milk.
The active substance is regorafenib.
Preferred are regorafenib and the monohydrate of regorafenib as a compound of the present invention.
Studies on the carcinogenic potential of regorafenib have not been performed.
In rats, regorafenib or its metabolites are excreted in milk.
Two major and six minor metabolites of regorafenib have been identified in plasma.
Preference is given to the hydrochloride, mesylate or phenylsulfonate salt of regorafenib.
Table 1, thermodynamic solubility of regorafenib monohydrate in different solvents.
See also
The composition of any of claims 1 to 9 comprising a solid dispersion comprising regorafenib.
The composition of claim 1 comprising regorafenib as active ingredient.
In one embodiment, the small molecule multi-kinase inhibitor comprises sorafenib or regorafenib.
An international phase 3 clinical trial showed regorafenib helps prolong survival.
In case of vomiting after regorafenib administration, the patient should not take additional tablets.
Women of childbearing potential must be informed that regorafenib may cause foetal harm.
The pharmacokinetics of regorafenib has not been studied in patients with end-stage renal disease.
Patients receiving placebo who experienced disease progression were offered open-label regorafenib cross-over option.
In addition, regorafenib has shown anti-metastatic effects in vivo.
For gastrointestinal stromal tumor, the disease has progressed after treatment with imatinib, sunitinib, or regorafenib.
Regorafenib could harm infant growth and development see section 5.3.
Example A, HPMC based coated tablet comprising regorafenib for comparison.
Regorafenib ( Stivarga ® ) is approved for the treatment of some patients with metastatic colorectal cancer.
Results from animal studies indicate that regorafenib can impair male and female fertility see section 5.3.
Table 3, Stability results of tablets containing regorafenib.
The concentration-time profile indicates that regorafenib and its metabolites may undergo enterohepatic circulation see section 5.2.
Table 2, Composition of tablets containing regorafenib.
This indicates that co-administration of regorafenib may increase systemic exposure to UGT1A1 and UGT1A9 substrates.
For GIST, patient must have progressed on imatinib, sunitinib or regorafenib.
The mean daily regorafenib dose received was 140 mg.
Package Leaflet, Information for the user Stivarga 40 mg film-coated tablets regorafenib.
Example 1, Coated tablet comprising regorafenib Solid dispersion.
Age did not affect the regorafenib pharmacokinetics over the studied age range 29 - 85 years.
Each film-coated tablet contains 40 mg of regorafenib.
In vitro protein binding of regorafenib to human plasma proteins is high 99.5.
